Northern Trust Corp Raises Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Northern Trust Corp grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,457,848 shares of the biopharmaceutical company’s stock after acquiring an additional 135,826 shares during the period. Northern Trust Corp’s holdings in Dynavax Technologies were worth $18,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 1,169 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Dynavax Technologies in the fourth quarter worth $71,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on DVAX. The Goldman Sachs Group cut their target price on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research report on Thursday, April 17th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. JMP Securities dropped their target price on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $24.00.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $9.62 on Wednesday. The company has a market capitalization of $1.16 billion, a P/E ratio of 53.44 and a beta of 1.26. The company’s 50-day simple moving average is $12.16 and its two-hundred day simple moving average is $12.57. Dynavax Technologies Co. has a one year low of $9.28 and a one year high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. As a group, equities analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.